New preprint from the lab! Our awesome @lillianwu.bsky.social drove this project with contributions from @kezlane.bsky.social @alison-harrod.bsky.social and collaborators @andrea-musacchio.bsky.social @chromatinlab.bsky.social and @claudioalfieri.bsky.social
#CENP-B
www.biorxiv.org/content/10.6...

Fantastic talk by Max Douglas @icr.ac.uk on telomere replication and protection at Sussex @sussex.ac.uk @gdsc-sussex.bsky.social today! Check out his latest work on bioRxiv: doi.org/10.1101/2025...

AI to predict how bowel cancer patients will respond to new NHS drug PhenMap tool could spare thousands of patients from treatment that would be ineffective for them

AI to predict how #BowelCancer patients will respond to new NHS drug, by @raphaelboyd.bsky.social in @theguardian.com ⤵️

www.theguardian.com/society/2026...

Sophie Umhofer, who was diagnosed with stage four bowel cancer in 2018, aged 36. The text overlaying the image of Sophie says: "Help give everyone with bowel cancer the hope of a cure". The ICR's logo is also visible and URL for ICR.ac.uk/HopeOfACure

Our world-class scientists are pushing the boundaries of research to shape a future in which bowel cancer is more preventable, predictable and treatable.

Please support us today to drive forward bold new research, to help us make more discoveries and save more lives ⤵️

ICR.ac.uk/HopeOfACure

A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancer - Scientific Reports We introduce a comprehensive multi-step machine-learning driven pipeline which fuses multi-modal omics datasets and clinical outcomes with survival and treatment response to predict patient outcome fo...

The #MachineLearning study was published in the @natureportfolio.nature.com journal Scientific Reports.

Read the paper ⤵️

doi.org/10.1038/s415...

Scientists develop new way to determine which patients will respond best to bowel cancer treatment Scientists develop new way to determine which patients will respond best to bowel cancer treatment

Read more about the research, which could help guide treatment for #BowelCancer patients in the future ⤵️

www.icr.ac.uk/about-us/icr...

Professor Anguraj Sadanandam, Professor in Stratification and Precision Medicine at the ICR, pictured in a lab coat. He is quoted saying: “Our research uses advanced AI methods to pull together large amounts of complex data, helping us to spot patterns that would otherwise be impossible for a human to see, and to uncover the clues hidden within a patient’s tumour. “In future, I hope this approach will lead to a test that can be used by clinicians, to ensure patients receive personalised care that has the highest chance of working against their cancer.”

Professor Anguraj Sadanandam at the ICR led the research with Professor Annette Byrne from @rcsi.bsky.social.

The next stage will be to validate their method in more patient samples, and to develop it into a test that could be used in a prospective clinical trial, to help guide treatment decisions.

Professor Anguraj Sadanandam working in a lab with a colleague.

Now, scientists at the ICR and RCSI University of Medicine and Health Sciences, Dublin, have developed an AI-based method to identify the patients most likely to benefit from the drug, and those least likely to respond.

Bevacizumab treatment

The targeted drug, bevacizumab, was approved in December for treating advanced bowel cancer patients on the NHS. It slows the growth of cancer, but it only works for a small group of patients and carries the risk of serious side effects.

Mini tumours grown from a bowel cancer.

🔬 ICR and @rcsi.bsky.social scientists have developed a new way to determine which patients will respond best to #BowelCancer treatment – potentially sparing thousands of patients from treatments that won’t work for them.

Read more in our🧵

#AI #ArtificialIntelligence #CancerResearch

Cases of bowel cancer in young adults are increasing at an alarming rate: there are too many stories like Bradley's, a young man who died from bowel cancer in his early twenties. @icr.ac.uk are fundraising so we can lead more research to prevent and better treat bowel cancer at all ages.

Today we launch our appeal to give everyone with bowel cancer the hope of a cure.

Our world-class scientists are pushing the boundaries of research to shape a future in which bowel cancer is more preventable, predictable and treatable.

Please support us today: www.icr.ac.uk/support-us/o...

If you work on quantitative cancer genomics, please consider submitting an abstract for our next "Cancer Population Genetics Club" #CANPOP meeting hosted @icr.ac.uk on 15 June 2026.

CANPOP is free to attend. Registration & abstract submission here: docs.google.com/forms/d/e/1F...

Robin Weiss obituary Scientist who established productive growth of HIV in an immortalised cell line, which led to the development of the UK’s first antibody test for the virus

Professor Robin Weiss, Director of the ICR (1980-1989), is remembered in @theguardian.com by Professor Jonathan Weber (@imperialcollegeldn.bsky.social).

Read about Robin's important contributions to cancer and HIV/AIDS research ⤵️

www.theguardian.com/science/2026...

Three weeks today, Steve Phillips will be running the London Marathon to raise funds for our groundbreaking research, inspired by his mum, who was diagnosed with four cancers in four years. Read his story here: www.icr.ac.uk/research-and...

💡 New research is shining a light on the hidden costs of living with and beyond breast cancer in the UK.

At the 15th European Breast Cancer Conference, Patrick Kierkegaard, (the Centre's Implementation Science Lead) spoke to the Daily Mail about findings from the CASCARA programme.

“Running the Marathon is my thank you to those who researched my type of cancer” - Abi’s London Marathon story Abi Sherratt, 27, was diagnosed with papillary thyroid cancer in February 2025. She is preparing to run the London Marathon on 26 April.

🏃‍♀️🎽 Abi Sherratt, 27, was diagnosed with papillary thyroid cancer in February 2025. She will be running the London Marathon later this month to raise funds for our vital research.

👉 Read Abi’s story here: www.icr.ac.uk/research-and...

How Evolution Is Shaping Cancer Research YouTube video by The Rest Is Science

🎧 Have you listened to the latest episode of The Rest is Science?

This episode is a cancer research takeover, and it covers the work of ICR’s Dr Alejandra Bruna, who is investigating how children’s cancers adapt and evolve to resist treatment.

youtu.be/hAjvmBReo-8

Its a honour to be appointed as a NIHR Senior Investigator. The NIHR has kept research at the forefront of the NHS and allows us to perform patient centric, scientifically robust research. @icr.ac.uk @royalmarsden.org @nihr.bsky.social

MP Feryal Clark (left) stood next to Dr Annie Baker for a photo taken during a recent International Women's Day event

The event celebrated the achievements of women across Feryal’s constituency of Enfield North.

Annie shared her journey so far as a woman in science and highlighted the pioneering research taking place at the ICR.

🎉It was great to see Dr Annie Baker, a Senior Staff Scientist in our Genomics and Evolutionary Dynamics Group at the ICR, speak at a recent International Women’s Day event hosted by her local MP @feryalclark.bsky.social

🔬 How can we better harness the immune system to fight cancer?

Our next #ConvergingOnCancer seminar will explore how researchers are enhancing anti-tumour immune responses through cross-disciplinary approaches.

📅 16th April, 10-11am

Great to see CSC students Aria, Saki & Shania inspiring the next generation at an @icr.ac.uk careers event 👏

6th-form students visited labs, explored #CancerResearch careers, and heard directly from scientists 🧪 Huge thanks to everyone who took part, these moments really help open up #STEM pathways

New study reveals key enzyme as hidden driver of cancer stress responses New study reveals key enzyme as hidden driver of cancer stress responses

As HSF1 is hard to target directly, DHX8 may offer an indirect way to weaken cancer’s defences. It’s early days, and much more research is needed, but this discovery opens an exciting new path for future therapeutic research.

More here ⤵️

When researchers disabled DHX8, cancer cells lost their protective stress‑response network, which slowed their growth and, in some cases, led to cell death. Encouragingly, healthy cells were far less affected.

🔬Our researchers have uncovered a previously hidden role of the enzyme DHX8, which helps cancer cells survive stress by enabling the activity of the powerful stress‑response protein HSF1.

We hosted ~50 Year 12 students at our Chelsea labs yesterday for a look into cancer research! 🔬

We shared progress on our game we’re developing that explores life and work in the lab! It’s all part of our mission to help students see a future for themselves in the lab

#PublicEngagement #STEM

bsky.app/profile/icrl...

Scientists discover new avenue for treating an aggressive form of breast cancer Scientists discover new avenue for treating an aggressive form of breast cancer

A big step toward new targeted treatments for one of the hardest‑to‑treat breast cancers.

More here ⤵️

In ~60% of TNBC cases, HORMAD1 switches on where it shouldn’t, disrupting a key safety checkpoint. The team identified drugs that can target this flaw, and Aurora B inhibitors already in trials reduced tumour growth in mice.